Research has shown ACSL4 is preferentially expressed in basal-like breast cancer cell lines, promoting ferroptosis, while it is often silenced in most luminal-type breast cancer cell lines that are resistant to ferroptosis, suggesting that ACSL4 determines ferroptosis sensitivity in breast cancer [194]. This evidence concerns the gene ACSL4 and breast carcinoma.